Details for Patent: 9,701,636

Which drugs does patent 9,701,636 protect, and when does it expire?

Patent 9,701,636 protects VAFSEO and is included in one NDA.

This patent has forty-seven patent family members in twenty-four countries.

Summary for Patent: 9,701,636

Title:	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Abstract:	Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Inventor(s):	James Densmore Copp, Ann W. Newman, Anne Luong
Assignee:	Akebia Therapeutics Inc
Application Number:	US14/541,284
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,701,636
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 9,701,636

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-001	Mar 27, 2024		RX	Yes	No			Y	Y
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-002	Mar 27, 2024		RX	Yes	No			Y	Y
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,701,636

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	099354
Australia	2014348523
Australia	2019202144